I need a presentation on EU MDR 2017/745, when it was first published, exact date, when…
- User
I need a presentation on EU MDR 2017/745, when it was first published, exact date, when it was supposed to be implemented in 2020, why it was delayed till May 2021 for final implementation, what is derogation that made the MDD Certificates and legacy devices to be available till 31st December 2027 for Class IIb and Class III devices and till 31st December 2028 for class IIa devices, what is legacy device, what is MDD full form and its number MDD 93/42/EEC, what is a EU MDR Regulation Device, how the transition till December 2027 will work, how many articles in EU MDR, How many annexes in EU MDR and list of Annexes for EU MDR, brief about GSPR, SSCP, PSUR, PMCF, CER max slides 20 to 25
- Assistant
Presentation on EU MDR 2017/745
Slide 1: Title Slide
- Title: European Union Medical Device Regulation (EU MDR) 2017/745
- Subtitle: An Overview and Key Transition Details
- Presenter's Name
- Date
Slide 2: Introduction
- Brief overview of the importance of medical device regulation in the EU
- Transition from MDD to MDR
- Objectives of the presentation
Slide 3: Publication of EU MDR 2017/745
- Exact Publication Date: 5 May 2017
- Published in the Official Journal of the European Union
- Entry into force: 25 May 2017
- Initiation of transition period from MDD to MDR
Slide 4: Original Implementation Timeline
- Initial Date of Application: 26 May 2020
- Three-year transition period for manufacturers to comply
- Purpose: Allow time for adaptation to new requirements
Slide 5: Delay in Implementation to May 2021
- Reason for Delay:
- COVID-19 Pandemic
- Global health crisis impacted stakeholders' ability to comply
- Official Postponement:
- EU Parliament and Council adopted Regulation (EU) 2020/561
- Deferred application by one year to 26 May 2021
- COVID-19 Pandemic
Slide 6: Extension of MDD Certificates and Legacy Devices
- Derogation Explanation:
- Amendments to extend validity of certain MDD certificates
- Class IIb and III Devices:
- Extended availability until 31 December 2027
- Class IIa Devices:
- Extended availability until 31 December 2028
- Purpose:
- Prevent device shortages
- Ensure continuous supply of safe medical devices
Slide 7: What is a Legacy Device?
- Definition:
- Devices with valid certificates under MDD or AIMDD prior to MDR date of application
- Characteristics:
- Not yet MDR certified but can still be marketed
- Importance:
- Allows manufacturers time to transition to MDR compliance
- Ensures no disruption in the availability of essential medical devices
Slide 8: Medical Devices Directive (MDD) 93/42/EEC
- Full Form: Medical Device Directive
- Directive Number: 93/42/EEC
- Adoption Date: 14 June 1993
- Purpose:
- Harmonize medical device laws within the EU
- Relevance:
- Predecessor to the EU MDR
Slide 9: What is an EU MDR Device?
- Definition:
- Medical devices compliant with Regulation (EU) 2017/745
- Key Features:
- Enhanced safety and performance requirements
- Stricter clinical evidence standards
- Increased transparency and traceability (e.g., UDI system)
Slide 10: Transition Process until December 2027
- Phased Approach:
- Gradual compliance requirements based on device class
- Key Deadlines:
- Class III and IIb: Transition by 31 December 2027
- Class IIa: Transition by 31 December 2028
- Manufacturer Obligations:
- Maintain compliance with MDD/AIMDD
- Begin preparations for MDR certification
- Notified Bodies:
- Limited capacity; early engagement recommended
Slide 11: Total Number of Articles in EU MDR
- Articles: 123
- Structure:
- Divided into 10 chapters
Slide 12: Total Number of Annexes in EU MDR
- Annexes: 17
- List of Annexes:
- Annex I: General Safety and Performance Requirements (GSPR)
- Annex II: Technical Documentation
- Annex III: Technical Documentation on Post-Market Surveillance
- Annex IV: EU Declaration of Conformity
- Annex V: CE Marking of Conformity
- Annex VI: Information to be Submitted Upon Registration
- Annex VII: Requirements for Notified Bodies
- Annex VIII: Classification Rules
- Annex IX: Conformity Assessment Based on a Quality Management System and Technical Documentation
- Annex X: Conformity Assessment Based on Type Examination
- Annex XI: Conformity Assessment Based on Product Conformity Verification
- Annex XII: Certificates Issued by a Notified Body
- Annex XIII: Procedure for Custom-Made Devices
- Annex XIV: Clinical Evaluation and Post-Market Clinical Follow-up
- Annex XV: Clinical Investigations
- Annex XVI: Products Without an Intended Medical Purpose
- Annex XVII: Correlation Table
Slide 13: General Safety and Performance Requirements (GSPR)
- Overview:
- Detailed in Annex I
- Purpose:
- Set essential requirements for safety and performance
- Key Components:
- Risk management
- Performance evaluation
- Biological safety
- Labeling and instructions for use
- Manufacturer Responsibilities:
- Demonstrate compliance through technical documentation
Slide 14: Summary of Safety and Clinical Performance (SSCP)
- Definition:
- Document providing accessible information about a device's safety and clinical performance
- Applicability:
- Required for Class III and implantable devices
- Content Includes:
- Device description
- Intended use
- Clinical benefits
- Risks and warnings
- Audience:
- Healthcare professionals and patients
- Transparency Goal:
- Enhances informed decision-making
Slide 15: Periodic Safety Update Report (PSUR)
- Purpose:
- Regular reporting of safety-related data post-market
- Requirements:
- Mandatory for Class IIa, IIb, and III devices
- Content Includes:
- Conclusions of risk-benefit determination
- Main findings of the Post-Market Surveillance (PMS) data
- Volume of sales and usage frequency
- Submission:
- Periodic updates to Notified Bodies and authorities
Slide 16: Post-Market Clinical Follow-up (PMCF)
- Definition:
- Continuous process updating clinical evaluation
- Objectives:
- Confirm safety and performance in real-world use
- Identify previously unknown risks
- Ensure continued acceptability of benefit-risk ratio
- Activities May Include:
- Observational studies
- Patient registries
- Surveys
- Integration with PMS:
- Part of the manufacturer's Post-Market Surveillance Plan
Slide 17: Clinical Evaluation Report (CER)
- Purpose:
- Documentation of clinical evidence demonstrating compliance with GSPR
- Components:
- Clinical data analysis
- Evaluation of clinical performance and safety
- Literature review and clinical investigation results
- Updates:
- Regularly updated throughout the device lifecycle
- Regulatory Importance:
- Essential for conformity assessment and CE marking
Slide 18: Impact on Manufacturers
- Increased Responsibilities:
- Stricter documentation and reporting requirements
- Quality Management System Enhancements:
- Align with MDR requirements
- Strategic Planning:
- Early engagement with Notified Bodies
- Resource allocation for compliance activities
Slide 19: Challenges and Considerations
- Resource Intensiveness:
- Financial and personnel investments
- Notified Body Availability:
- Limited capacity may cause delays
- Market Readiness:
- Need for thorough understanding of MDR requirements
- Innovation Impact:
- Balancing compliance with product development
Slide 20: Conclusion
- Recap of Key Points:
- Transition from MDD to MDR
- Extended timelines and their implications
- Key components of the MDR (GSPR, SSCP, PSUR, PMCF, CER)
- Call to Action:
- Importance of proactive compliance efforts
- Staying informed on regulatory updates
Slide 21: Q&A Session
- Prompt for Audience Questions
- Contact Information:
- Phone Number
Slide 22: References
- Official Documents:
- Regulation (EU) 2017/745
- Regulation (EU) 2020/561
- Guidance Materials:
- European Commission's MDR guidance
- Websites:
- European Commission Medical Devices
- Notified Bodies' resources
Notes for Presenter:
- Ensure Accuracy:
- Verify all dates and regulatory details with official sources
- Engagement:
- Use visual aids like timelines and charts to illustrate transitions
- Customization:
- Tailor content depth based on audience expertise
- Updates:
- Stay informed about any regulatory changes post-2023
Brief Explanations of Key Terms:
- GSPR (General Safety and Performance Requirements):
- Fundamental criteria that devices must meet to ensure safety and performance.
- SSCP (Summary of Safety and Clinical Performance):
- A summary report intended to provide public access to safety and performance information of high-risk devices.
- PSUR (Periodic Safety Update Report):
- Regularly updated report on the safety of a device post-market.
- PMCF (Post-Market Clinical Follow-up):
- Ongoing process of collecting clinical data to confirm the safety and performance of a device after it has been placed on the market.
- CER (Clinical Evaluation Report):
- Comprehensive analysis of clinical data pertaining to a device to verify its clinical safety and performance.
Final Slide:
- Thank You!
- Closing Remark:
- Emphasize the importance of compliance for patient safety and market success
This presentation provides a structured overview of the EU MDR 2017/745, covering its publication, implementation delays, transition processes, and key regulatory components. It is designed to fit within 20 to 25 slides and offers brief explanations of critical elements such as GSPR, SSCP, PSUR, PMCF, and CER.